Feuerstein Throws BioMarin Into Gilead Takeover Speculation

When people talk Gilead Sciences, Inc. GILD takeover possibilities, TESARO Inc TSRO and Incyte Corporation INCY commonly surface.

But biotech reporter Adam Feuerstein posited a less conventional interest — orphan-drug company BioMarin Pharmaceutical Inc. BMRN.

“It’s a little bit counterintuitive,” Feuerstein said Wednesday on Benzinga’s PreMarket Prep show. “They would sort of be complementary to each other in that they’re bringing in a whole ‘nother business.”

Gilead is such a large company that identifying path-altering acquisition targets is difficult, but “BioMarin is a big enough company to really move the needle at Gilead.”

In Other News

Outside of the M&A sphere, Feuerstein looks favorably on Editas Medicine Inc EDIT but noted it's too early to properly assess the impact of the biotech’s first therapy.

“The whole crisper technology is really super interesting, but it’s also very early,” he said. “They have not started human clinical trials of their crisper-based therapy yet, so it’s one of those things where you’re going to have to wait a while to see real data.”

See Also: Adam Feuerstein Sees Major Price Manipulation In Small-Cap Pharma Stocks

PreMarket Prep is a daily trading ideas show with a focus on pre-market volatility and technical setups. You can listen live and chat with our hosts, guests, and listeners every morning from 8-9 a.m. ET here or on YouTube Live. You can listen to the podcast on iTunes, Soundcloud and Sticher.